Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 525-532

  Khanna, Anchit ^a   Pimanda, John E ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

biomarker; CHK1; CIP2A; DNA PKc; drug resistance; MYC; P53; patient stratification; personalized medicine; PP2A; prognostic role; tumor grade

Indexed keywords

BORTEZOMIB; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CELASTROL; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE; ONCOPROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; CHECKPOINT KINASE 1; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN KINASE; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CIP2A GENE; COLON CANCER; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; LEUKEMIA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; NEOPLASMS; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

AUTOANTIGENS; BIOMARKERS, TUMOR; GENES, MYC; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; PROGNOSIS; PROTEIN KINASES;

EID: 84955732770     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29431     Document Type: Review

References (80)

1. Nolan C, Krebs EG, Fischer EH, et al., Further studies on site phosphorylated in phosphorylase B to a reaction. Biochemistry 1964; 3: 542.
2. Zhang Q, Claret FX,. Phosphatases: the new brakes for cancer development? Enzyme Res 2012;2012: 659649
3. Sontag JM, Sontag E,. Regulation of cell adhesion by PP2A and SV40 small tumor antigen: an important link to cell transformation. Cell Mol Life Sci 2006; 63: 2979-91.
4. Arroyo JD, Hahn WC,. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746-55.
5. Sablina AA, Hector M, Colpaert N, et al., Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010; 70: 10474-84.
6. Westermarck J, Hahn WC,. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-60.
7. Janssens V, Rebollo A,. The role and therapeutic potential of ser/thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 2012; 12: 268-87.
8. Kim HS, Song MC, Kwak IH, et al., Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J Biol Chem 2003; 278: 37497-510.
9. Arnold HK, Sears RC,. A tumor suppressor role for PP2A-B56 alpha through negative regulation of c-myc and other key oncoproteins. Cancer Metast Rev 2008; 27: 147-58.
10. Wurzenberger C, Gerlich DW,. Phosphatases: providing safe passage through mitotic exit. Nat Rev Mol Cell Bio 2011; 12: 469-82.
11. Khanna A, Pimanda JE, Westermarck J,. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 2013; 73: 6548-53.
12. De P, Carlson J, Leyland-Jones B, et al., Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget 2014; 5: 4581-602.
13. Khanna A, Okkeri J, Westermarck J., Gene Section. Available at: http://AtlasGeneticsOncology.org 2010: 976.
14. Junttila MR, Puustinen P, Niemela M, et al., CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
15. Soo Hoo L, Zhang JY, Chan EK,. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002; 21: 5006-15.
16. Khanna A, Bockelman C, Hemmes A, et al,. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101: 793-805.
17. Khanna A, Okkeri J, Bilgen T, et al., ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PloS One 2011; 6: e17979
18. Laine A, Sihto H, Come C, et al., Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013; 3: 182-97.
19. Niemela M, Kauko O, Sihto H, et al., CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012; 31: 4266-78.
20. Khanna A, Kauko O, Böckelman C, et al., Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res 2013; 73: 6757-69.
21. Mathiasen DP, Egebjerg C, Andersen SH, et al., Identification of a c-jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-myc levels in ras transformation. Oncogene 2012; 31: 390-401.
22. Khanna A, Böckelman C, Laine A, et al., Constitutive DNA-damage signaling promotes cancer cell proliferation through Chk1-CIP2A pathway. EJC Suppl 2010; 8: 217
23. Khanna A, Böckelman C, Westermarck J, et al., 6650 Myc-dependent regulation and prgonostic role of myc stabilizing protein, CIP2A, in human gastric cancer. Eur J Cancer Suppl 2009; 7: 403
24. Ventela S, Come C, Makela JA, et al., CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PloS One 2012; 7: e33209
25. Bockelman C, Lassus H, Hemmes A, et al,. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011; 105: 989-95.
26. Dong QZ, Wang Y, Dong XJ, et al., CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18: 857-65.
27. Xu P, Xu XL, Huang Q, et al., CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 2012; 29: 1643-7.
28. Bockelman C, Koskensalo S, Hagstrom J, et al., CIP2A overexpression is associated with c-myc expression in colorectal cancer. Cancer Biol Ther 2012; 13: 289-95.
29. Teng HW, Yang SH, Lin JK, et al., CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012; 16: 1037-47.
30. Wiegering A, Pfann C, Uthe FW, et al., CIP2A influences survival in colon cancer and is critical for maintaining myc expression. PloS One 2013; 8: e75292
31. Come C, Laine A, Chanrion M, et al., CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092-100.
32. Yu G, Liu G, Dong J, et al., Clinical implications of CIP2A protein expression in breast cancer. Med Oncol 2013; 30: 524
33. Liu X, Chai Y, Li J, et al., Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. Tumour Biol 2014; 35: 2661-7.
34. He H, Wu G, Li W, et al., CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012; 21: 143-9.
35. Huang P, Qiu J, You J, et al., Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 2012; 17: 422-9.
36. Huang LP, Adelson ME, Mordechai E, et al., CIP2A expression is elevated in cervical cancer. Cancer Biomark 2010; 8: 309-17.
37. Liu J, Wang X, Zhou G, et al., Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol 2011; 122: 430-6.
38. Huang LP, Savoly D, Sidi AA, et al., CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 2012; 1: 76-81.
39. Xue Y, Wu G, Wang X, et al., CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol 2013; 30: 406
40. Khanna A, Patil R, Deshmukh A,. Assessment of the potential of pathological stains in human prostate cancer. J Clin Diagn Res 2014; 8: 124-8.
41. Vaarala MH, Vaisanen MR, Ristimaki A,. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29: 136
42. Qu W, Li W, Wei L, et al., CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2012; 29: 113-8.
43. Shi F, Ding Y, Ju S, et al., Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers 2014; 19: 70-6.
44. Xu P, Huang Q, Xie F, et al., Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology 2013; 60: 669-72.
45. Liu N, He QM, Chen JW, et al., Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer 2014; 13: 111
46. Wang L, Gu F, Ma N, et al., CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 2013; 34: 2309-13.
47. Zhai M, Cong L, Han Y, et al., CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol 2014; 35: 1123-8.
48. Bockelman C, Hagstrom J, Makinen LK, et al., High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011; 104: 1890-5.
49. Lucas CM, Harris RJ, Giannoudis A, et al., Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011; 117: 6660-8.
50. Cristobal I, Garcia-Orti L, Cirauqui C, et al., PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606-14.
51. Khanna A,. Regulation of cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-jun NH 2-terminal kinases (JNKs), SP600125, in human fibrosarcoma (HT1080) cells. F1000Research 2013; 2.
52. Lee JW, Soung YH, Kim SY, et al., Mutational analysis of MYC in common epithelial cancers and acute leukemias. APMIS 2006; 114: 436-9.
53. Soucek L, Whitfield J, Martins CP, et al., Modelling myc inhibition as a cancer therapy. Nature 2008; 455: 679-83.
54. Wang H, Mannava S, Grachtchouk V, et al., cMyc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008; 27: 1905-15.
55. Janghorban M, Farrell AS, Allen-Petersen BL, et al., Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 2014; 111: 9157-62.
56. Ferrao PT, Bukczynska EP, Johnstone RW, et al., Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012; 31: 1661-72.
57. Hoglund A, Nilsson LM, Muralidharan SV, et al., Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 2011; 17: 7067-79.
58. Murga M, Campaner S, Lopez-Contreras AJ, et al., Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18: 1331-5.
59. Dent P, Tang Y, Yacoub A, et al., CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11: 133-40.
60. Mujtaba T, Dou QP,. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011; 12: 471-80.
61. Chen KF, Yu HC, Liu CY, et al., Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Therap 2011; 10: 892-901.
62. Hou DR, Huang AC, Shiau CW, et al., Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition. Molecules 2013; 18: 15398-411.
63. Yu HC, Hou DR, Liu CY, et al., Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PloS One 2013; 8: e55705
64. Liu CY, Shiau CW, Kuo HY, et al., Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 2013; 98: 729-38.
65. Lin YC, Chen KC, Chen CC, et al., CIP2A-mediated akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012; 48: 585-93.
66. Tseng LM, Liu CY, Chang KC, et al., CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012; 14: R68
67. Ding Y, Wang Y, Ju S, et al., Role of CIP2A in the antitumor effect of bortezomib in colon cancer. Mol Med Rep 2014; 10: 387-92.
68. Chen KF, Liu CY, Lin YC, et al., CIP2A mediates effects of bortezomib on phospho-akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-66.
69. Ling X, Calinski D, Chanan-Khan AA, et al., Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res 2010; 29: 8
70. Richardson PG, Barlogie B, Berenson J, et al., A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
71. Li X, Lu Y, Liang K, et al., Differential responses to doxorubicin-induced phosphorylation and activation of akt in human breast cancer cells. Breast Cancer Res 2005; 7: R589-97.
72. Choi YA, Park JS, Park MY, et al., Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011; 585: 755-60.
73. Laine A, Westermarck J,. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin Cancer Res 2014; 20: 3644-50.
74. Ewald JA, Desotelle JA, Wilding G, et al., Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102: 1536-46.
75. Nardella C, Clohessy JG, Alimonti A, et al., Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-11.
76. Yu HC, Chen HJ, Chang YL, et al., Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 2013; 85: 356-66.
77. Wang CY, Chao TT, Chang FY, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF,. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer 2014; 85: 152-60.
78. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
79. Liu Z, Ma L, Wen ZS, et al., Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 2014; 35: 905-14.
80. Liu Z, Ma L, Wen ZS, et al., Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med Chem Lett 2014; 5: 113-8.